BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32222327)

  • 1. Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
    Gonzalez R; Gockley AA; Melamed A; Sugrue R; Clark RM; Del Carmen MG; Growdon W; Berkowitz RS; Horowitz NS; Worley MJ
    Gynecol Oncol; 2020 Jun; 157(3):700-705. PubMed ID: 32222327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of beta blockers on epithelial ovarian cancer survival.
    Diaz ES; Karlan BY; Li AJ
    Gynecol Oncol; 2012 Nov; 127(2):375-8. PubMed ID: 22819786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
    Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
    Watkins JL; Thaker PH; Nick AM; Ramondetta LM; Kumar S; Urbauer DL; Matsuo K; Squires KC; Coleman RL; Lutgendorf SK; Ramirez PT; Sood AK
    Cancer; 2015 Oct; 121(19):3444-51. PubMed ID: 26301456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.
    Couttenier A; Lacroix O; Silversmit G; Vaes E; De Schutter H; Robert A
    Cancer Epidemiol; 2019 Oct; 62():101579. PubMed ID: 31450179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Hanley GE; Kaur P; Berchuck A; Chase A; Grout B; Deurloo CM; Pike M; Richardson J; Terry KL; Webb PM; Pearce CL
    Gynecol Oncol; 2021 Aug; 162(2):461-468. PubMed ID: 34090707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.
    Melamed A; Nitecki R; Boruta DM; Del Carmen MG; Clark RM; Growdon WB; Goodman A; Schorge JO; Rauh-Hain JA
    Obstet Gynecol; 2017 May; 129(5):861-869. PubMed ID: 28383367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
    Majidi A; Na R; Dixon-Suen S; Jordan SJ; Webb PM
    Gynecol Oncol; 2020 Jun; 157(3):678-685. PubMed ID: 32317171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
    Seagle BL; Graves S; Strohl AE; Shahabi S
    Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of statin therapy on survival in epithelial ovarian cancer.
    Elmore RG; Ioffe Y; Scoles DR; Karlan BY; Li AJ
    Gynecol Oncol; 2008 Oct; 111(1):102-5. PubMed ID: 20698078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage-specific associations between beta blocker use and prognosis after colorectal cancer.
    Jansen L; Hoffmeister M; Arndt V; Chang-Claude J; Brenner H
    Cancer; 2014 Apr; 120(8):1178-86. PubMed ID: 24415516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
    Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
    Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Chen X
    Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.